Scott Gottlieb, MD

“A therapy that can cure disease in a single treatment isn’t a unit of drug. It’s a public health solution.”

Scott Gottlieb, M.D., served as the 23rd Commissioner of the U.S. Food and Drug Administration (FDA), where he focused on advancing public health through developing and implementing innovative approaches to improving medical outcomes, reshaping healthcare delivery, and expanding consumer choice and safety. Under his leadership, the FDA advanced a record-setting number of approvals of novel drugs, medical devices, and generic medicines, in addition to new frameworks for the modern and safe and effective oversight of gene therapies, cell based regenerative medicines, targeted drugs, and digital health devices.

Previously, Dr. Gottlieb served as the FDA’s Deputy Commissioner for Medical and Scientific Affairs and Senior Adviser to the Administrator of the Centers for Medicare and Medicaid Services on the implementation of the Medicare drug benefit. He was appointed by the Senate to serve on the Federal Health Information Technology Policy Committee, which advises the Department of Health and Human Services on healthcare information technology.

Dr. Gottlieb is currently a Resident Fellow at the American Enterprise Institute (AEI), where he continues his work on improving public health through entrepreneurship and medical innovation and on expanding regulatory approaches to maintain patient and physician autonomy. He is also a Partner at venture capital firm New Enterprise Associates; a member of the Boards of Directors of Pfizer, Illumina, Aetion, and Tempus; and an elected member of the National Academy of Medicine.

He obtained his B.A. in economics from Wesleyan University and his M.D. from Mount Sinai, where he completed his residency in internal medicine. A former practicing hospitalist and Clinical Assistant Professor at the New York University School of Medicine, Dr. Gottlieb is widely published in leading medical journals and periodicals, including The Wall Street Journal, The New York Times, and The Washington Post. He has held editorial positions on the British Medical Journal and the Journal of the American Medical Association and appears regularly as a guest commentator on CNBC.